Compare ANIX & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIX | PFX |
|---|---|---|
| Founded | 1982 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.9M | 86.7M |
| IPO Year | 2013 | 2010 |
| Metric | ANIX | PFX |
|---|---|---|
| Price | $3.00 | $43.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 203.7K | 942.0 |
| Earning Date | 09-09-2026 | 12-11-2026 |
| Dividend Yield | N/A | ★ 3.27% |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $145.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $38.30 |
| 52 Week High | $5.46 | $56.48 |
| Indicator | ANIX | PFX |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 49.65 |
| Support Level | $2.77 | $41.86 |
| Resistance Level | $3.09 | $44.56 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 47.65 | 83.15 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.